Drug intelligence / Profile preview

⁶⁸Ga-ABS011

Lead developer
Curium
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

⁶⁸Ga-ABS011 is an investigational gallium-68-labeled positron emission tomography (PET) radiodiagnostic tracer designed to target human epidermal growth factor receptor 2 (HER2). It consists of a single-domain antibody (sdAb) conjugated to a NOTA chelator and radiolabeled with gallium-68. The tracer is designed to bind HER2 rapidly while unbound tracer clears quickly from the bloodstream, enabling same-day, whole-body PET imaging of HER2 expression across multiple lesions. This non-invasive approach helps reveal spatial heterogeneity in HER2 status that single-lesion biopsies may miss, thereby guiding patient selection and therapy monitoring in HER2-driven solid tumors, such as breast and gastric cancers. Originally developed by Abscint SA (a spin-off from Vrije Universiteit Brussel), the global rights to develop, manufacture, and commercialize the asset were acquired by Curium in 2026.

Other names
68Ga-ABS01168Ga-NOTA-HER2-sdAb68Ga-NOTA-anti-HER2-sdAb[68Ga]Ga-NOTA-HER2-sdAb[68Ga]Ga-NOTA-anti-HER2-sdAb
02

Identity

Drug type
Antibody-Based Therapeutics
Originator
ABSCINT
Modality
Antibody FragmentsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
gastric cancer and precursor lesionsPreclinicalActive
metastatic breast cancer (mBC)In developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
273
Drugs in the lead indication
676

Lead indication: metastatic breast cancer (mBC)

Most advanced in the lead indication

  1. neratinibApproved
  2. trastuzumab deruxtecanApproved
  3. trastuzumab emtansineApproved
  4. lapatinibApproved
  5. abemaciclibApproved

Beyond the preview

Go deeper on ⁶⁸Ga-ABS011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ⁶⁸Ga-ABS011.

Work on ⁶⁸Ga-ABS011? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call